Datadog Inc vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Datadog Inc trades at $275.06 (market cap $97.43B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.34 (market cap $2.28B). The key difference: Datadog Inc is far larger — about 42.7× SELLAS Life Sciences Group Inc. Common Stock's market cap, and Datadog Inc is trading nearer its 52-week high, SELLAS Life Sciences Group Inc. Common Stock nearer its low. Which is the better fit depends on your goals.
| DDOG | SLS | |
|---|---|---|
Market Cap | $97.43B | $2.28B |
Volume | 1,586,926 | 3,128,960 |
Sector | Technology | Health |
52-Week High | $288.15 | $15.46 |
52-Week Low | $102.62 | $1.39 |
Typical Hold Time | 76 Days | — |
Enterprise Value | $93.72B | $2.15B |
Signals from Pluang's Aura AI — not financial advice
Datadog (DDOG) trades at $273.8, down 1.6% on the day, yet maintains a bullish technical stance with strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue growth remains robust, climbing from $1.7B in 2022 to $3.4B in 2025, though net income margins are volatile. Positive sentiment is fueled by AI-driven demand and global expansion, as highlighted in recent financial media.
The outlook is cautiously optimistic given high valuation multiples (P/E 542.68) and negative net cash flow, but strong revenue growth and a dominant buy rating consensus (83.34%) suggest upside to the $276.10 price target. Key risks include competitive pressures and reliance on enterprise cloud spending cycles.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered as software-as-a-service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of different applications throughout their businesses.
Read more on DDOG →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →